Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials | BMC Cancer | Full Text

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials | BMC Cancer | Full Text

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib. The study aimed to identify pre-...

Authors:Ashley M. Hopkins, Akash D. Rathod, Andrew Rowland, Ganessan Kichenadasse and Michael J. Sorich

Citation:BMC Cancer 2020 20:157

Content type:Research article

Published on: 27 February 2020

• ViewFull Text
 
• ViewPDF